| Literature DB >> 26608400 |
Ahlem Ben-Haj-Ayed1, Adnène Moussa2, Randa Ghedira1, Sallouha Gabbouj3, Souad Miled4, Nadia Bouzid5, Sameh Tebra-Mrad5, Noureddine Bouaouina5, Lotfi Chouchane6, Abdelfattah Zakhama2, Elham Hassen7.
Abstract
Indoleamine 2,3-dioxygenase (IDO) is an enzyme with an immunosuppressive effect whose function is diverted by tumor cells to counteract immune cell functions, inducing immune escape of tumor cells. The aim of this study was to investigate the clinical significance of IDO in nasopharyngeal carcinoma (NPC). Compared to controls, NPC patients' plasma IDO activity was significantly higher, especially among patients with metastatic cancer (p=0.005). The immunohistochemical analysis revealed that high IDO expression was observed in 74% of NPC tissues and the epithelial IDO expression was inversely correlated to T-cell infiltration. Kaplan-Meier survival analysis showed that whatever the localization, intratumoral or stromal, patients with a high IDO expression and low T-cell infiltration have significantly lower survival rates. Moreover, in multivariate analysis, intratumoral and stromal IDO expression were found to be independent prognostic factors for disease-free survival (p=0.016; HR: 3.52) and overall survival (p=0.015; HR: 4.76) respectively. Our findings provide evidence that IDO is involved in tumor immune evasion of NPC, suggesting that it could be a relevant therapeutic target for NPC.Entities:
Keywords: Indoleamine 2,3-dioxygenase; Nasopharyngeal carcinoma; Survivals; T-cell infiltration
Mesh:
Substances:
Year: 2015 PMID: 26608400 DOI: 10.1016/j.imlet.2015.11.012
Source DB: PubMed Journal: Immunol Lett ISSN: 0165-2478 Impact factor: 3.685